BioSpace News Archive

Sinovant Sciences and Renexxion today announced the initiation of a collaboration to pursue the development of naronapride, an investigational gastrointestinal prokinetic, in Greater China.

Third annual study from Quest Diagnostics of health plan executives and physicians suggests physicians need better tools, data access and less complex quality measures to spur adoption

Nemaura Medical Inc. announced it has placed an initial order with its designated UK-based contract manufacturer for 12,500 sugarBEAT® rechargeable transmitters

200,000 Square Foot State-of-the-Art Plant Built to Support Development of mRNA Medicines

The licensed TCRm antibodies were developed under a research collaboration and license agreement between Eureka Therapeutics and Boehringer Ingelheim established in 2015.

July 17, 2018 12:30 UTC Teva Highlights Key Milestones Achieved in the 2017 Social Impact Report JERUSALEM--( BUSINESS WIRE )-- Today, Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) published its annual social impact report, highlighting achievements related to the two pillars that drive the Company’s initiatives: building healthy communities and leading a responsible business. Teva’s 2017 Social Impact Repor

The Company’s ROOT OF SIGHT technology uses three-dimensional retina sheets created from human stem cells, transplanted into the back of the eye, to replace lost retina and improve visual acuity.

MarketLab announced that it has expanded its product portfolio to include hundreds of new CLIA-waived testing supplies to address an underserved need in the health care marketplace.

The most recent quarterly results of a study conducted by Spherix Global Insights with 100 US rheumatologists reveals that the user-base for Eli Lilly’s Taltz has more than doubled since the first quarter of 2018 while use of Pfizer’s Xeljanz has remained relatively flat after a strong showing in Q1.

High-resolution electrocardiography strongly supports OMT-28’s claim for low pro-arrhythmic risk